 |
| Date | Title | | | 02/25/10 | Exenatide Once Weekly New Drug Application Review Extended By FDA Due to Weather-Related Closure| SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass., Feb 25, 2010 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company
(NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today confirmed that the
U.S. Food and Drug Administration (FDA) has set a new Prescription Drug
User Fee Act (PDUFA) action date of March 12 for its review of the
exenatide once weekly new drug application (NDA). The revised action
date is the result of the FDA's... |
|  | | 02/22/10 | Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity| Phase 2 Extension Study Demonstrated Sustained Weight LossSAN DIEGO and OSAKA, Japan, Feb. 22, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program foll... |
| | | 01/27/10 | Amylin Pharmaceuticals Reports 2009 Financial Results| 2009 Non-GAAP Operating Loss Improves by 57% Over 2008SAN DIEGO, Jan. 27, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2009. The Company reported total revenue of $758.4 million for the year ended December 31, 2009, which includes net product sales of $754.0 million. Non-GAAP operating loss was $58.7 million for the year, compared to $137.2 million for 2008. Net loss excluding restructuri... |
| | | 01/20/10 | Amylin Pharmaceuticals to Webcast Year-End Financial Results| SAN DIEGO, Jan. 20, 2010 /PRNewswire via COMTEX/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2009 on Wednesday, January 27, 2010 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the fourth quarter and year ended December 31, 2009.
The call will be webcast live throug... |
| |
|
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
